219 related articles for article (PubMed ID: 10197639)
1. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.
Tozer GM; Prise VE; Wilson J; Locke RJ; Vojnovic B; Stratford MR; Dennis MF; Chaplin DJ
Cancer Res; 1999 Apr; 59(7):1626-34. PubMed ID: 10197639
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
Tozer GM; Prise VE; Wilson J; Cemazar M; Shan S; Dewhirst MW; Barber PR; Vojnovic B; Chaplin DJ
Cancer Res; 2001 Sep; 61(17):6413-22. PubMed ID: 11522635
[TBL] [Abstract][Full Text] [Related]
3. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.
Prise VE; Honess DJ; Stratford MR; Wilson J; Tozer GM
Int J Oncol; 2002 Oct; 21(4):717-26. PubMed ID: 12239609
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine.
Tozer GM; Prise VE; Chaplin DJ
Cancer Res; 1997 Mar; 57(5):948-55. PubMed ID: 9041200
[TBL] [Abstract][Full Text] [Related]
5. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K
Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406
[TBL] [Abstract][Full Text] [Related]
6. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide.
Parkins CS; Holder AL; Hill SA; Chaplin DJ; Tozer GM
Br J Cancer; 2000 Sep; 83(6):811-6. PubMed ID: 10952787
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
Chaplin DJ; Pettit GR; Hill SA
Anticancer Res; 1999; 19(1A):189-95. PubMed ID: 10226542
[TBL] [Abstract][Full Text] [Related]
8. The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.
Brooks AC; Kanthou C; Cook IH; Tozer GM; Barber PR; Vojnovic B; Nash GB; Parkins CS
Anticancer Res; 2003; 23(4):3199-206. PubMed ID: 12926054
[TBL] [Abstract][Full Text] [Related]
9. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
Galbraith SM; Chaplin DJ; Lee F; Stratford MR; Locke RJ; Vojnovic B; Tozer GM
Anticancer Res; 2001; 21(1A):93-102. PubMed ID: 11299795
[TBL] [Abstract][Full Text] [Related]
10. Exploring vascular dysfunction caused by tirapazamine.
Huxham LA; Kyle AH; Baker JH; McNicol KL; Minchinton AI
Microvasc Res; 2008 Mar; 75(2):247-55. PubMed ID: 18023823
[TBL] [Abstract][Full Text] [Related]
11. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.
Holwell SE; Cooper PA; Grosios K; Lippert JW; Pettit GR; Shnyder SD; Bibby MC
Anticancer Res; 2002; 22(2A):707-11. PubMed ID: 12017147
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
Holwell SE; Cooper PA; Thompson MJ; Pettit GR; Lippert LW; Martin SW; Bibby MC
Anticancer Res; 2002; 22(6C):3933-40. PubMed ID: 12553015
[TBL] [Abstract][Full Text] [Related]
13. Effect of endothelin-1 and sarafotoxin S6c on blood flow in a rat tumor.
Bell KM; Prise VE; Chaplin DJ; Tozer GM
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S222-5. PubMed ID: 8587370
[TBL] [Abstract][Full Text] [Related]
14. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.
Pedley RB; Hill SA; Boxer GM; Flynn AA; Boden R; Watson R; Dearling J; Chaplin DJ; Begent RH
Cancer Res; 2001 Jun; 61(12):4716-22. PubMed ID: 11406542
[TBL] [Abstract][Full Text] [Related]
15. Hemorrhagic shock-induced vascular hyporeactivity in the rat: relationship to gene expression of nitric oxide synthase, endothelin-1, and select cytokines in corresponding organs.
Liu LM; Dubick MA
J Surg Res; 2005 May; 125(2):128-36. PubMed ID: 15854664
[TBL] [Abstract][Full Text] [Related]
16. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.
Malcontenti-Wilson C; Muralidharan V; Skinner S; Christophi C; Sherris D; O'Brien PE
Clin Cancer Res; 2001 Apr; 7(4):1052-60. PubMed ID: 11309357
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses.
Tozer GM; Prise VE; Lewis G; Xie S; Wilson I; Hill SA
Clin Cancer Res; 2009 Jun; 15(11):3781-90. PubMed ID: 19470729
[TBL] [Abstract][Full Text] [Related]
18. Effects of nitric oxide synthase inhibition on blood flow and survival in experimental skin flaps.
Gribbe O; Samuelson UE; Wiklund NP
J Plast Reconstr Aesthet Surg; 2007; 60(3):287-93. PubMed ID: 17293287
[TBL] [Abstract][Full Text] [Related]
19. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark GG; Hill SA; Prise VE; Tozer GM; Pettit GR; Chaplin DJ
Cancer Res; 1997 May; 57(10):1829-34. PubMed ID: 9157969
[TBL] [Abstract][Full Text] [Related]
20. Effects of nitric oxide donor and nitric oxide synthase inhibitor on the resistance, exchange and capacitance functions of the canine intestinal vasculature.
Hsieh NK; Chang HR; Hu CT; Chen HI
Vascul Pharmacol; 2008; 48(2-3):122-8. PubMed ID: 18295548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
